Perrigo Company director Orlando D. Ashford reported compensation-related share movements. On May 13 2026, he received 24,363 Restricted Stock Units (RSUs), each representing a right to one ordinary share, scheduled to vest on May 13 2027.
On May 14 2026, 10,669 RSUs converted into the same number of ordinary shares, treated as a derivative exercise at a reference price of $10.84 per share. To cover tax obligations, 5,122 ordinary shares were withheld the same day as a tax-withholding disposition, rather than an open-market sale. After these transactions, Ashford directly held 27,717 ordinary shares, reflecting a net increase in ownership driven by equity compensation.
Perrigo Company plc director Kevin Francis Egan reported compensation-related equity activity, not open-market trading. On May 13, 2026, he received a grant of 16,681 Restricted Stock Units (RSUs), each representing one ordinary share and vesting on future dates as disclosed.
On May 14, 2026, 7,305 RSUs were converted into the same number of ordinary shares, and 3,507 ordinary shares were disposed of to cover tax obligations at a value of $10.84 per share. Following the tax-withholding disposition, 3,798 ordinary shares from that vesting event remained directly held. No remaining derivative position from the exercised RSUs is shown in this filing.
Perrigo Company plc director Jonas Samuelson reported compensation-related equity activity involving Restricted Stock Units (RSUs) and ordinary shares. On May 13 2026, he received a grant of 16,681 RSUs, each representing a contingent right to one ordinary share and scheduled to vest on May 13 2027.
On May 14 2026, 7,305 RSUs vested and were converted into ordinary shares. To satisfy tax obligations, 3,507 ordinary shares were disposed of at $10.84 per share through a tax-withholding transaction. Following these transactions, Samuelson directly owned 5,392 ordinary shares, with the new 16,681-unit RSU award remaining outstanding and unexercised.
Perrigo Company plc director Jonas Samuelson filed an amended Form 4 to correct a prior report of shares withheld to cover taxes on vested restricted stock units. On 6 March 2026, 3,066 Restricted Stock Units converted into 3,066 ordinary shares, and 1,472 ordinary shares were disposed of to satisfy tax-withholding obligations, not through an open-market sale. Following these transactions, Samuelson holds 1,594 ordinary shares directly.
T. Rowe Price Associates, Inc. reports beneficial ownership of 14,016,148 shares of Perrigo Co plc common stock, representing 10.2% of the class. The filing states sole voting power for 13,658,349 shares and sole dispositive power for 13,707,794.
T. Rowe Price Associates, Inc. amends its Schedule 13G/A to report ownership in Perrigo Co plc common stock. The filing states 13,376,708 shares beneficially owned, representing 9.7% of the class. It shows sole voting power of 13,327,263 and sole dispositive power of 13,376,708. The filing also identifies T. Rowe Price Mid‑Cap Value Fund with 7,498,410 shares (5.4%). The filing is signed by a T. Rowe Price Vice President.
Perrigo Company plc reported a sharp first‑quarter loss driven by large non‑cash impairments and restructuring costs. Net sales were $969.2 million, down from $1,043.9 million a year earlier, as Self Care, Specialty Care and All Other all declined modestly while Infant Formula was roughly flat.
The company recorded $330.8 million of goodwill impairments tied to Women’s Health, Infant Formula and Oral Care reporting units, plus $75.1 million of restructuring charges, turning operating income of $46.9 million last year into an operating loss of $372.3 million. Net loss from continuing and discontinued operations widened to $398.6 million, or $2.87 per diluted share, compared with a $6.4 million loss, or $0.05 per share, in the prior‑year period.
Cash used in operating activities was $113.6 million, and cash and cash equivalents fell to $357.2 million from $531.6 million at year‑end 2025. Total borrowings were $3,632.5 million, including $970.0 million of term loans and $2,262.2 million of notes and bonds. Perrigo also completed an amended credit agreement, drew $427.6 million on its revolver to repay Term Loan A, and completed the sale of its Dermacosmetics business after quarter‑end for up to €332.6 million in consideration.
Perrigo Company plc reported a large first‑quarter 2026 loss driven by a non‑cash goodwill impairment but kept its full‑year outlook. All In net sales from continuing operations fell to $969.2 million, down 7.2% year over year, with Core net sales down 8.3% as weaker cough, cold and other categories offset share gains.
Reported gross margin declined to 33.6% and reported operating margin dropped to (38.4)% after a $330.8 million goodwill impairment and higher restructuring charges. Reported diluted EPS from continuing operations was $(2.81), while All In adjusted diluted EPS was $0.43, down from $0.60. Specialty Care grew net sales 4.0% with stronger Women’s Health brands such as Opill and ellaOne, while Self Care net sales fell 11.5%.
After quarter end, Perrigo completed the sale of its Dermacosmetics business, receiving about €305.6 million in upfront cash expected to support debt reduction. Management reaffirmed 2026 guidance, including All In adjusted EPS of $2.00–$2.30 and Core adjusted EPS of $2.25–$2.55, and continues to highlight second‑half improvement despite current category and macro headwinds.
Perrigo Company plc held its 2026 Annual General Meeting of Shareholders on April 30, 2026. Shareholders approved the new 2026 Long-Term Incentive Plan, which became effective immediately and replaces the company’s 2019 long-term incentive plan.
All listed director nominees were elected with strong majorities; for example, Bradley A. Alford received 105,969,898 votes for and 1,290,063 against. Shareholders also voted on additional proposals that received substantial levels of support, with several items drawing more than 110 million votes in favor and limited opposition or abstentions.
Perrigo Company plc has completed the sale of its branded Dermacosmetics business to Karo Healthcare for total consideration of up to €332.6 million. The deal includes €305.6 million in upfront cash, with €5.6 million from net working capital adjustments, and up to €27.0 million of contingent consideration tied to net sales milestones over three years. In calendar 2025, the Dermacosmetics business generated about €120 million of net sales and around 5% of Perrigo’s adjusted operating income, so the divestiture is meaningful but not company‑defining. Perrigo expects to use the net proceeds primarily to reduce debt, which it believes will improve financial flexibility and strengthen its balance sheet.
For 2025, Perrigo reported consolidated continuing net sales of $4,253.1 million and a reported operating loss of $1,122.2 million, driven largely by $1.3 billion of goodwill impairment and other charges. After adjustments for amortization, restructuring, litigation, impairments and other items, adjusted operating income was $622.3 million, or 14.6% of net sales, equivalent to €551.4 million using a 0.8860 EUR/USD exchange rate.